The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of oral rigosertib in patients with advanced solid tumors.
Daniel W. Bowles
No relevant relationships to disclose
Jennifer Robinson Diamond
No relevant relationships to disclose
Elaine Tat Lam
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Onconova Therapeutics
Colin D. Weekes
No relevant relationships to disclose
Stephen Leong
No relevant relationships to disclose
Lia Gore
No relevant relationships to disclose
Christopher Hanyoung Lieu
No relevant relationships to disclose
Elizabeth Freas
No relevant relationships to disclose
Chen Ren
Stock Ownership - Onconova Therapeutics
Other Remuneration - Onconova Therapeutics
Francois Wilhelm
Employment or Leadership Position - Onconova Therapeutics (B)
Stock Ownership - Onconova Therapeutics (B)
Other Remuneration - Onconova Therapeutics (B)
S. Gail Eckhardt
Consultant or Advisory Role - Onconova Therapeutics
Honoraria - Onconova Therapeutics
Antonio Jimeno
Research Funding - Onconova Therapeutics